Please login to the form below

Not currently logged in

NICE recommendation

This page shows the latest NICE recommendation news and features for those working in and with pharma, biotech and healthcare.

Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma

Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma

BMS still has a chance to strike a deal in order to gain NICE recommendation, but Novartis will now have a head start. ... Novartis' recommendation was only possible thanks to price and access negotiations between it, NICE and NHS England.

Latest news

More from news
Approximately 2 fully matching, plus 132 partially matching documents found.

Latest Intelligence

  • Positive disruption in business intelligence Positive disruption in business intelligence

    Take the recent recommendation by NICE, the UK’s drug-spending policymaker, of Kadcyla, the breast cancer treatment launched by Roche. ... In December 2016, NICE issued draft guidance indicating Kadcyla was too expensive for routine funding on the NHS.

  • Rare diseases: meeting the challenge Rare diseases: meeting the challenge

    Companies will still need to work hard to win a NICE ‘yes’recommendation, and may still yet have to accept optimised - as NICE calls them - or restricted - as industry calls them - ... None of the four therapies approved to date under the NICE HST

  • The death of the cancer drugs fund? The death of the cancer drugs fund?

    evidence to support a recommendation for routine commissioning, and where additional evidence would be likely to enable a more informed NICE appraisal decision. “ ... positive recommendation at which point it would move out of the Fund into mainstream

  • Transforming times at AstraZeneca Transforming times at AstraZeneca

    She gives the example of a drug to prevent a second heart attack that has a positive NICE recommendation, can save people's lives and reduce further hospital costs. “ ... It sounds like good value and NICE has also said it is,” says Anson. “

  • Creating a 21st century life sciences ecosystem Creating a 21st century life sciences ecosystem

    England's health technology assessor NICE, which decides which drugs the NHS should pay for. “ ... So, where you do get a licensing approval, then a NICE recommendation, there isn't such a long delay to get uptake.".

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...